Prelude Financial Statements From 2010 to 2025

PRLD Stock

USD 2.94 0.49 20.00%

Prelude Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Prelude Therapeutics' valuation are provided below:

Gross Profit

10.5 M

Market Capitalization

154 M

Enterprise Value Revenue

11.1349

Revenue

10.5 M

Earnings Share

(1.47)

There are over one hundred nineteen available trending fundamental ratios for Prelude Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to check out all of Prelude Therapeutics' recent performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. As of December 29, 2025, Market Cap is expected to decline to about 66.3 M. In addition to that, Enterprise Value is expected to decline to about 71.6 M

Check Prelude Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Prelude Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 982.6 K, Interest Expense of 1.6 M or Selling General Administrative of 20.7 M, as well as many indicators such as Price To Sales Ratio of 11.0, Dividend Yield of 0.0 or PTB Ratio of 0.77. Prelude financial statements analysis is a perfect complement when working with Prelude Therapeutics Valuation or Volatility modules.

Build AI portfolio with Prelude Stock

Check out the analysis of Prelude Therapeutics Correlation against competitors.

For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.

Prelude Therapeutics Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

195 M

175.5 M

97.9 M

Slightly volatile

Other Current Liabilities

10.2 M

15.2 M

5.2 M

Slightly volatile

Total Current Liabilities

16.8 M

25.6 M

9 M

Slightly volatile

Other Liabilities

4.1 M

3.9 M

1.2 M

Slightly volatile

Property Plant And Equipment Net

37.2 M

35.5 M

8.4 M

Slightly volatile

Accounts Payable

5.4 M

7.7 M

3.2 M

Slightly volatile

Cash

11.9 M

12.5 M

30.6 M

Pretty Stable

Non Current Assets Total

41.6 M

39.6 M

10.1 M

Slightly volatile

Cash And Short Term Investments

174.8 M

133.6 M

88.2 M

Slightly volatile

Common Stock Shares Outstanding

48.5 M

75.8 M

23.1 M

Slightly volatile

Liabilities And Stockholders Equity

195 M

175.5 M

97.9 M

Slightly volatile

Non Current Liabilities Total

17.5 M

18.4 M

29 M

Slightly volatile

Total Liabilities

28.6 M

44.1 M

37 M

Pretty Stable

Property Plant And Equipment Gross

42.8 M

40.7 M

9.3 M

Slightly volatile

Total Current Assets

177.2 M

135.9 M

89.3 M

Slightly volatile

Non Current Liabilities Other

1.8 M

3.1 M

969.6 K

Slightly volatile

Net Working Capital

160.4 M

110.3 M

80.4 M

Slightly volatile

Property Plant Equipment

8.1 M

7.7 M

2.9 M

Slightly volatile

Short and Long Term Debt Total

18.9 M

18 M

3.9 M

Slightly volatile

Other Current Assets

2.8 M

2.3 M

1.9 M

Slightly volatile

Short Term Debt

1.8 M

2.7 M

864.7 K

Slightly volatile

Non Currrent Assets Other

5 M

4.2 M

1.9 M

Slightly volatile

Other Assets

11.4 M

10.8 M

3 M

Slightly volatile

Common Stock Total Equity

3.2 K

3.6 K

3.9 K

Slightly volatile

Deferred Long Term Liabilities

240.8 K

270.9 K

295.4 K

Slightly volatile

Common Stock

5.3 K

5.8 K

4.4 K

Slightly volatile

Current Deferred Revenue

11.9 M

13.3 M

14.5 M

Slightly volatile

Prelude Therapeutics Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Depreciation And Amortization

982.6 K

1.8 M

526.7 K

Slightly volatile

Selling General Administrative

20.7 M

28.7 M

10.7 M

Slightly volatile

Other Operating Expenses

97.1 M

146.7 M

52.2 M

Slightly volatile

Research Development

76.4 M

118 M

41.5 M

Slightly volatile

Cost Of Revenue

1.5 M

1.8 M

747 K

Slightly volatile

Total Operating Expenses

97.1 M

146.7 M

52.2 M

Slightly volatile

Reconciled Depreciation

987.5 K

1.8 M

529 K

Slightly volatile

Total Other Income Expense Net

13.2 M

12.5 M

3.2 M

Slightly volatile

Selling And Marketing Expenses

935.2 K

1.1 M

Slightly volatile

Prelude Therapeutics Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Stock Based Compensation

15.7 M

21.3 M

7.3 M

Slightly volatile

Begin Period Cash Flow

57.2 M

29.3 M

31.9 M

Slightly volatile

Depreciation

982.6 K

1.8 M

526.7 K

Slightly volatile

Capital Expenditures

725.8 K

764 K

1 M

Slightly volatile

End Period Cash Flow

15.7 M

16.5 M

31.9 M

Pretty Stable

Change To Netincome

35.6 M

33.9 M

10 M

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

11.0

12.38

13.4954

Slightly volatile

Stock Based Compensation To Revenue

2.44

2.74

2.9919

Slightly volatile

Capex To Depreciation

0.41

0.4312

2.7379

Slightly volatile

EV To Sales

8.62

9.69

10.5664

Slightly volatile

Payables Turnover

0.19

0.2292

0.1704

Slightly volatile

Sales General And Administrative To Revenue

3.28

3.69

4.0255

Slightly volatile

Research And Ddevelopement To Revenue

13.49

15.17

16.5406

Slightly volatile

Capex To Revenue

0.088

0.0982

0.1071

Slightly volatile

Cash Per Share

1.67

1.7626

7.019

Slightly volatile

Days Payables Outstanding

2 K

1.6 K

2.6 K

Slightly volatile

Income Quality

0.91

0.809

0.8597

Slightly volatile

Current Ratio

8.1

5.2999

8.1208

Slightly volatile

Capex Per Share

0.0096

0.0101

0.2031

Slightly volatile

Revenue Per Share

0.0738

0.0831

0.0906

Slightly volatile

Interest Debt Per Share

0.25

0.2378

0.0599

Slightly volatile

Debt To Assets

0.11

0.1027

0.0257

Slightly volatile

Days Of Payables Outstanding

2 K

1.6 K

2.6 K

Slightly volatile

Ebt Per Ebit

1.05

0.9102

0.9731

Pretty Stable

Quick Ratio

8.1

5.2999

8.1208

Slightly volatile

Net Income Per E B T

1.06

1.07

0.9932

Pretty Stable

Cash Ratio

0.46

0.4865

5.3517

Slightly volatile

Free Cash Flow Operating Cash Flow Ratio

1.13

1.0074

1.0403

Pretty Stable

Fixed Asset Turnover

0.16

0.18

0.194

Slightly volatile

Debt Ratio

0.11

0.1027

0.0257

Slightly volatile

Price Sales Ratio

11.0

12.38

13.4954

Slightly volatile

Asset Turnover

0.0319

0.0359

0.0391

Slightly volatile

Prelude Therapeutics Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

66.3 M

69.8 M

257.1 M

Pretty Stable

Enterprise Value

71.6 M

75.4 M

230 M

Pretty Stable

Prelude Fundamental Market Drivers

Prelude Upcoming Events

	20th of March 2024 Upcoming Quarterly Report	View
	13th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	20th of March 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Prelude Therapeutics Financial Statements

Prelude Therapeutics stakeholders use historical fundamental indicators, such as Prelude Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Prelude Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Prelude Therapeutics' assets and liabilities are reflected in the revenues and expenses on Prelude Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Prelude Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Current Deferred Revenue	13.3 M	11.9 M
Total Revenue	7 M	7.3 M
Cost Of Revenue	1.8 M	1.5 M
Stock Based Compensation To Revenue	2.74	2.44
Sales General And Administrative To Revenue	3.69	3.28
Research And Ddevelopement To Revenue	15.17	13.49
Capex To Revenue	0.10	0.09
Revenue Per Share	0.08	0.07
Ebit Per Revenue	(17.96)	(18.86)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

DD	Dupont De Nemours
CRDO	Credo Technology Group
GOOG	Alphabet Inc Class C

When determining whether Prelude Therapeutics is a strong investment it is important to analyze Prelude Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Prelude Therapeutics' future performance. For an informed investment choice regarding Prelude Stock, refer to the following important reports:

How To Invest In Prelude

Details

Is Prelude Stock a good investment?

Details

What is Prelude Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Prelude Therapeutics Correlation against competitors.

For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.

You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.47)

Revenue Per Share

0.138

Quarterly Revenue Growth

1.167

Return On Assets

(0.52)

Return On Equity

(1.04)

The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Prelude Financial Statements From 2010 to 2025

Prelude Therapeutics Balance Sheet

Prelude Therapeutics Income Statement

Prelude Therapeutics Cash Flow Statement

Financial Ratios

Prelude Therapeutics Valuation Data

Prelude Fundamental Market Drivers

Prelude Upcoming Events

About Prelude Therapeutics Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY